JAGX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

4.21M

+19.98%

-4.260

-96.61%

3.67M

+65.76%

-2.040

-87.78%

4.24M

+42.33%

-1.490

-85.48%

Estimates Revision

The market is revising No Change the revenue expectations for Jaguar Health, Inc. (JAGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -54.35%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-54.35%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Jaguar Health Inc (JAGX.O) is -0.11, compared to its 5-year average forward P/E of -2.11. For a more detailed relative valuation and DCF analysis to assess Jaguar Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.11

Current PE

-0.11

Overvalued PE

1.15

Undervalued PE

-5.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.34

Current EV/EBITDA

-8.95

Overvalued EV/EBITDA

15.96

Undervalued EV/EBITDA

-11.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.35

Current PS

0.27

Overvalued PS

9.43

Undervalued PS

-2.73

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JAGX News & Events

Events Timeline

No data

News

9.0

2025-12-10Newsfilter

Jaguar Health Extends Conditional Approval for Canalevia-CA1 Until December 2026

1.0

2025-12-10Globenewswire

88th Emerging Growth Conference Scheduled for December 10-11, 2025

9.5

2025-11-25Benzinga

Keysight Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

People Also Watch

Frequently Asked Questions

What is Jaguar Health Inc (JAGX) stock price today?

The current price of JAGX is 1.05 USD — it has decreased -2.78 % in the last trading day.

What is Jaguar Health Inc (JAGX)'s business?

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

What is the price predicton of JAGX Stock?

Wall Street analysts forecast JAGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAGX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Jaguar Health Inc (JAGX)'s revenue for the last quarter?

Jaguar Health Inc revenue for the last quarter amounts to 3.08M USD, decreased -0.80 % YoY.

What is Jaguar Health Inc (JAGX)'s earnings per share (EPS) for the last quarter?

Jaguar Health Inc. EPS for the last quarter amounts to -6.28 USD, decreased -76.11 % YoY.

What changes have occurred in the market's expectations for Jaguar Health Inc (JAGX)'s fundamentals?

How many employees does Jaguar Health Inc (JAGX). have?

Jaguar Health Inc (JAGX) has 49 emplpoyees as of January 10 2026.

What is Jaguar Health Inc (JAGX) market cap?

Today JAGX has the market capitalization of 4.38M USD.